

Hugo Vanderstichele

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10949982/hugo-vanderstichele-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

11,219
citations

45
h-index

91
g-index

91
ext. papers

12,436
ext. citations

5.8
avg, IF

5.32
L-index

#	Paper	IF	Citations
89	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid and tau. <i>Alzheimers and Dementia</i> , 2021 , 17, 1575-1582	1.2	12
88	Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for β synuclein measurement. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1653-1661	5.9	1
87	First amyloid β -42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimers and Dementia</i> , 2020 , 16, 1493-1503	1.2	20
86	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. <i>Journal of Neurochemistry</i> , 2019 , 149, 139-157	6	8
85	Antibody-based methods for the measurement of β synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019 , 149, 126-138	6	26
84	Cerebrospinal Fluid Total and Phosphorylated β synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019 , 56, 3476-3483	6.2	15
83	Ultrasensitive Detection of Plasma Amyloid- β s a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimers Disease</i> , 2019 , 71, 775-783	4.3	29
82	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 871-882	6	45
81	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2518-2530	5.3	10
80	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. <i>SLAS Technology</i> , 2018 , 23, 188-197	3	3
79	Plasma A β (Amyloid- β) Levels and Severity and Progression of Small Vessel Disease. <i>Stroke</i> , 2018 , 49, 884-890	6.7	14
78	Commutability of the certified reference materials for the standardization of β amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 2058-2066	5.9	23
77	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimers and Dementia</i> , 2018 , 14, 1313-1333	1.2	61
76	Plasma amyloid- β levels, cerebral atrophy and risk of dementia: a population-based study. <i>Alzheimers Research and Therapy</i> , 2018 , 10, 63	9	25
75	Relevance of A β 2/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 138	5.3	32
74	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimers Disease</i> , 2018 , 61, 169-183	4.3	16
73	C-Reactive Protein, Plasma Amyloid- β Levels, and Their Interaction With Magnetic Resonance Imaging Markers. <i>Stroke</i> , 2018 , 49, 2692-2698	6.7	20

72	CSF A β an excellent but complicated Alzheimer's biomarker - a route to standardisation. <i>Clinica Chimica Acta</i> , 2017 , 467, 27-33	6.2	82
71	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A β /A β ratio. <i>Alzheimers and Dementia</i> , 2017 , 13, 885-892	1.2	44
70	Accelerating drug development for Alzheimer's disease through the use of data standards. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 273-283	6	7
69	Plasma Amyloid- β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <i>Journal of Alzheimers Disease</i> , 2017 , 60, 977-987	4.3	26
68	Differential role of CSF fatty acid binding protein 3, β -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimers Research and Therapy</i> , 2017 , 9, 52	9	69
67	A user's guide for β -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017 , 32, 1117-1130	7	35
66	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, β -synuclein, and total tau in combination with A β (1-42)/A β (1-40). <i>Alzheimers Research and Therapy</i> , 2017 , 9, 40	9	12
65	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimers and Dementia</i> , 2017 , 13, 45-58 ^{1.2}		163
64	Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. <i>Alzheimers and Dementia</i> , 2017 , 13, 701-709	1.2	22
63	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimers Disease</i> , 2017 , 55, 19-35	4.3	29
62	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016 , 11, 65	19	13
61	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimers Research and Therapy</i> , 2016 , 8, 42	9	10
60	CSF A β 2/A β 0 and A β 2/A β 8 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 154-65	5.3	244
59	Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 1177-91	5.9	48
58	A First Tetraplex Assay for the Simultaneous Quantification of Total β -Synuclein, Tau, β -Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2016 , 11, e0153564	3.7	6
57	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimers Disease</i> , 2016 , 51, 97-106	4.3	17
56	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimers Disease</i> , 2016 , 54, 55-67	4.3	22
55	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimers and Dementia</i> , 2015 , 11, 772-91	1.2	53

54	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2	86
53	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 41-55	15 116
52	O4-11-06: The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers 2015 , 11, P298-P298	2
51	Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach. <i>Alzheimers Research and Therapy</i> , 2014 , 6, 23	9 3
50	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimers and Dementia</i> , 2014 , 10, 53-61	1.2 84
49	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimers and Dementia</i> , 2013 , 9, 251-61	1.2 289
48	Validation of assays for measurement of amyloid- β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. <i>Journal of Alzheimers Disease</i> , 2013 , 34, 897-910	4.3 15
47	Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. <i>Journal of Alzheimers Disease</i> , 2013 , 33, 117-31	4.3 34
46	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimers and Dementia</i> , 2012 , 8, 65-73	1.2 210
45	Improved protocol for measurement of plasma β amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. <i>Alzheimers and Dementia</i> , 2012 , 8, 250-60	1.2 45
44	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. <i>Methods</i> , 2012 , 56, 484-93	4.6 64
43	Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. <i>Journal of Alzheimers Disease</i> , 2012 , 31, 13-20	4.3 79
42	Potential sources of interference on A β immunoassays in biological samples. <i>Alzheimers Research and Therapy</i> , 2012 , 4, 39	9 10
41	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β 2. <i>Biomarkers in Medicine</i> , 2012 , 6, 409-17	2.3 66
40	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , 2012 , 6, 377-89	2.3 24
39	Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. <i>Clinical Chemistry</i> , 2012 , 58, 787-9	5.5 44
38	Validation of a multiplex assay for simultaneous quantification of amyloid- β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. <i>Journal of Alzheimers Disease</i> , 2012 , 32, 905-18	4.3 22
37	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimers and Dementia</i> , 2011 , 7, 386-395.e6	1.2 291

36	Validation of ELISA methods for quantification of total tau and phosphorylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. <i>Journal of Alzheimers Disease</i> , 2011 , 26, 531-41	4.3	19
35	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. <i>Acta Neuropathologica</i> , 2011 , 121, 597-609	14.3	220
34	Factors affecting A β plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011 , 122, 401-13	14.3	123
33	Comparison of analytical platforms for cerebrospinal fluid measures of A β amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. <i>Archives of Neurology</i> , 2011 , 68, 1137-44		138
32	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <i>Archives of Neurology</i> , 2010 , 67, 949-56		344
31	Evaluation of plasma A β (40) and A β (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 357-67	5.6	197
30	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010 , 31, 1867-76	5.6	53
29	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. <i>Annals of Neurology</i> , 2009 , 65, 403-13	9.4	1502
28	Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. <i>European Journal of Paediatric Neurology</i> , 2008 , 12, 334-41	3.8	17
27	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. <i>Neurobiology of Aging</i> , 2008 , 29, 812-8	5.6	84
26	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008 , 29, 1143-59	5.6	181
25	Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. <i>Journal of Alzheimers Disease</i> , 2007 , 12, 255-60	4.3	105
24	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006 , 44, 1472-80	5.9	100
23	Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. <i>Clinical Chemistry</i> , 2005 , 51, 336-45	5.5	358
22	Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. <i>Clinical Chemistry</i> , 2005 , 51, 189-95	5.5	137
21	Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. <i>Clinical Chemistry</i> , 2005 , 51, 1650-60	5.5	73
20	Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2005 , 51, 1057-60	5.5	8
19	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , 2004 , 61, 95-102		336

18	Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. <i>NeuroToxicology</i> , 2004 , 25, 471-80	4.4	16
17	Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. <i>Archives of Neurology</i> , 2004 , 61, 333-7		94
16	Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , 2003 , 179, 47-51	3.8	107
15	Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 16, 93-7	2.6	12
14	The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001 , 12, 257-64	2.6	81
13	Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. <i>Mechanisms of Ageing and Development</i> , 2001 , 122, 2005-11	5.6	39
12	Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. <i>Archives of Neurology</i> , 2001 , 58, 373-9		372
11	The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. <i>Journal of Cell Biology</i> , 2001 , 154, 731-40	7.3	143
10	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , 2001 , 297, 187-90	3.3	347
9	Tau and A β 2 in Cerebrospinal Fluid from Healthy Adults 21-83 Years of Age: Establishment of Reference Values. <i>Clinical Chemistry</i> , 2001 , 47, 1776-1781	5.5	351
8	Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. <i>Journal of Alzheimers Disease</i> , 2000 , 2, 199-206	4.3	160
7	Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. <i>Journal of Neuroscience</i> , 2000 , 20, 6452-8	6.6	100
6	Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. <i>American Journal of Pathology</i> , 2000 , 157, 1283-98	5.8	198
5	Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000 , 7, 245-58	2.7	268
4	Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. <i>Archives of Neurology</i> , 1999 , 56, 673-80		518
3	The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease. <i>American Journal of Human Genetics</i> , 1999 , 64, 290-2	11	43
2	Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. <i>Neurobiology of Disease</i> , 1999 , 6, 280-7	7.5	48
1	Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. <i>Nature</i> , 1998 , 391, 387-90	50.4	1580

